Considering that most of the patients with advanced forms of endometrial cancer have elevated HE4 and CA125 markers, and in the case of relapse, a vast majority of them show an increase in at least one of the assessed biomarkers. This evidence concerns the gene WFDC2 and endometrial cancer.